Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (TWEYES)
A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye
研究概览
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Borgomanero、意大利、28021
- Novartis Investigative Site
-
Galliate、意大利、28066
- Novartis Investigative Site
-
Napoli、意大利、80131
- Novartis Investigative Site
-
Napoli、意大利、80132
- Novartis Investigative Site
-
Napoli、意大利、80138
- Novartis Investigative Site
-
Pozzuoli、意大利、80078
- Novartis Investigative Site
-
-
AL
-
Alessandria、AL、意大利、15100
- Novartis Investigative Site
-
Casale Monferrato、AL、意大利、15033
- Novartis Investigative Site
-
-
AN
-
Ancona、AN、意大利、60126
- Novartis Investigative Site
-
-
BA
-
Acquaviva delle Fonti、BA、意大利、70021
- Novartis Investigative Site
-
Putignano、BA、意大利、70017
- Novartis Investigative Site
-
Terlizzi、BA、意大利、70038
- Novartis Investigative Site
-
-
BG
-
Bergamo、BG、意大利、24127
- Novartis Investigative Site
-
-
BL
-
Belluno、BL、意大利、32100
- Novartis Investigative Site
-
-
BO
-
Bologna、BO、意大利、40138
- Novartis Investigative Site
-
-
BS
-
Brescia、BS、意大利、25123
- Novartis Investigative Site
-
Desenzano del Garda、BS、意大利、25015
- Novartis Investigative Site
-
-
BZ
-
Bolzano、BZ、意大利、39100
- Novartis Investigative Site
-
-
CA
-
Cagliari、CA、意大利、09124
- Novartis Investigative Site
-
-
CB
-
Larino、CB、意大利
- Novartis Investigative Site
-
-
CE
-
Caserta、CE、意大利、81100
- Novartis Investigative Site
-
-
CH
-
Chieti、CH、意大利、66100
- Novartis Investigative Site
-
-
CN
-
Ceva、CN、意大利、12073
- Novartis Investigative Site
-
Cuneo、CN、意大利、12100
- Novartis Investigative Site
-
-
CO
-
Como、CO、意大利、22100
- Novartis Investigative Site
-
San Feramo Della Battaglia、CO、意大利、22020
- Novartis Investigative Site
-
-
CT
-
Acireale、CT、意大利、95024
- Novartis Investigative Site
-
Catania、CT、意大利、95124
- Novartis Investigative Site
-
Catania、CT、意大利、95123
- Novartis Investigative Site
-
-
CZ
-
Catanzaro、CZ、意大利、88100
- Novartis Investigative Site
-
-
FC
-
Forlì、FC、意大利、47100
- Novartis Investigative Site
-
-
FE
-
Cona、FE、意大利、44100
- Novartis Investigative Site
-
-
FG
-
Foggia、FG、意大利、71100
- Novartis Investigative Site
-
San Giovanni Rotondo、FG、意大利、71013
- Novartis Investigative Site
-
-
GE
-
Genova、GE、意大利、16132
- Novartis Investigative Site
-
Genova、GE、意大利、16153
- Novartis Investigative Site
-
Rapallo、GE、意大利、16035
- Novartis Investigative Site
-
-
KR
-
Crotone、KR、意大利、88074
- Novartis Investigative Site
-
-
LE
-
Tricase、LE、意大利、73039
- Novartis Investigative Site
-
-
LT
-
Terracina、LT、意大利、04019
- Novartis Investigative Site
-
-
ME
-
Messina、ME、意大利、98125
- Novartis Investigative Site
-
Milazzo、ME、意大利、98057
- Novartis Investigative Site
-
-
MI
-
Cinisello Balsamo、MI、意大利、20092
- Novartis Investigative Site
-
Legnano、MI、意大利、20025
- Novartis Investigative Site
-
Milano、MI、意大利、20132
- Novartis Investigative Site
-
Milano、MI、意大利、20122
- Novartis Investigative Site
-
Milano、MI、意大利、20123
- Novartis Investigative Site
-
Milano、MI、意大利、20100
- Novartis Investigative Site
-
Milano、MI、意大利、20142
- Novartis Investigative Site
-
Rozzano、MI、意大利、20089
- Novartis Investigative Site
-
Vizzolo Predabissi、MI、意大利、20070
- Novartis Investigative Site
-
-
NU
-
Nuoro、NU、意大利、08100
- Novartis Investigative Site
-
-
PA
-
Palermo、PA、意大利、90127
- Novartis Investigative Site
-
Palermo、PA、意大利、90146
- Novartis Investigative Site
-
-
PC
-
Piacenza、PC、意大利、29100
- Novartis Investigative Site
-
-
PD
-
Camposampiero、PD、意大利、35012
- Novartis Investigative Site
-
Monselice、PD、意大利、35043
- Novartis Investigative Site
-
Padova、PD、意大利、35128
- Novartis Investigative Site
-
Padova、PD、意大利、35100
- Novartis Investigative Site
-
-
PE
-
Pescara、PE、意大利、65124
- Novartis Investigative Site
-
-
PG
-
Citta' di Castello、PG、意大利、06012
- Novartis Investigative Site
-
Foligno、PG、意大利、06034
- Novartis Investigative Site
-
Perugia、PG、意大利、06100
- Novartis Investigative Site
-
-
PN
-
Pordenone、PN、意大利、33170
- Novartis Investigative Site
-
-
PR
-
Parma、PR、意大利、43100
- Novartis Investigative Site
-
-
PV
-
Pavia、PV、意大利、27100
- Novartis Investigative Site
-
-
RC
-
Reggio Calabria、RC、意大利、89124
- Novartis Investigative Site
-
-
RE
-
Correggio、RE、意大利、42015
- Novartis Investigative Site
-
Reggio Emilia、RE、意大利、42123
- Novartis Investigative Site
-
-
RM
-
Civitavecchia、RM、意大利、00053
- Novartis Investigative Site
-
Roma、RM、意大利、00168
- Novartis Investigative Site
-
Roma、RM、意大利、00161
- Novartis Investigative Site
-
Roma、RM、意大利、00133
- Novartis Investigative Site
-
Roma、RM、意大利、00184
- Novartis Investigative Site
-
Roma、RM、意大利、00189
- Novartis Investigative Site
-
Roma、RM、意大利、00186
- Novartis Investigative Site
-
-
RN
-
Riccione、RN、意大利、47838
- Novartis Investigative Site
-
-
SA
-
Eboli、SA、意大利、84025
- Novartis Investigative Site
-
Salerno、SA、意大利、84131
- Novartis Investigative Site
-
-
SO
-
Sondrio、SO、意大利、23100
- Novartis Investigative Site
-
-
SP
-
Sarzana、SP、意大利、19038
- Novartis Investigative Site
-
-
SS
-
Sassari、SS、意大利、07100
- Novartis Investigative Site
-
-
SV
-
Savona、SV、意大利、17100
- Novartis Investigative Site
-
-
TA
-
Taranto、TA、意大利、74100
- Novartis Investigative Site
-
-
TE
-
Teramo、TE、意大利、64100
- Novartis Investigative Site
-
-
TO
-
Torino、TO、意大利、10122
- Novartis Investigative Site
-
Torino、TO、意大利、10153
- Novartis Investigative Site
-
Torino、TO、意大利、10152
- Novartis Investigative Site
-
-
TR
-
Terni、TR、意大利、05100
- Novartis Investigative Site
-
-
TS
-
Trieste、TS、意大利、34129
- Novartis Investigative Site
-
-
TV
-
Conegliano、TV、意大利、31015
- Novartis Investigative Site
-
Treviso、TV、意大利、31100
- Novartis Investigative Site
-
-
UD
-
Udine、UD、意大利、33100
- Novartis Investigative Site
-
-
VA
-
Busto Arsizio、VA、意大利、21052
- Novartis Investigative Site
-
Somma Lombardo、VA、意大利、21019
- Novartis Investigative Site
-
Varese、VA、意大利、21100
- Novartis Investigative Site
-
-
VI
-
Santorso、VI、意大利、36014
- Novartis Investigative Site
-
Vicenza、VI、意大利、36100
- Novartis Investigative Site
-
-
VR
-
Legnago、VR、意大利、37045
- Novartis Investigative Site
-
Negrar、VR、意大利、37024
- Novartis Investigative Site
-
Verona、VR、意大利、37126
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria
Male or female patients aged 50 years or above Willing and capable to provide informed written consent Eye(s) eligible for ranibizumab treatment, with a BCVA below 2/10 due to wet AMD and/or Second eye eligible for ranibizumab treatment, with first eye treated (currently or previously) with ranibizumab, whichever BCVA. In bilateral wAMD patients, the second eye can be included only if the first eye has been treated at least 14 days before with ranibizumab
Exclusion Criteria:
Active intraocular inflammation (grade trace or above) in either eye Any ocular or periocular active infection (current or suspected), e.g. conjunctivitis, keratitis, scleritis, uveitis, endophtalmitis, in either eye Risk factors for retinal pigment epithelial tear (including pigment epithelial retinal detachment) Ocular disorders that may confound interpretation of results compromise visual acuity or require medical or surgical intervention during the study period including cataract, retinal vascular occlusion, retinal detachment or macular hole Uncontrolled glaucoma in either eye (IOP ≥ 30 mmHg on medication or according to investigator's judgment) History of vitrectomy in the study eye History of stroke or transient ischemic attack Systemic treatment with any VEGF inhibitor in the 90 days prior to study enrollment Ocular treatment of the study eye with any anti-angiogenic drugs within 1 month prior to study enrollment Any intraocular surgery in the study eye within 28 days prior to enrollment Women of childbearing potential UNLESS using effective contraception during treatment Pregnant or lactating women Simultaneous participation in a study that includes administration of any investigational drug Known hypersensitivity to ranibizumab or any component of the ranibizumab formulation Inability to comply with study procedures.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Ranibizumab
Administered as an Intravitreal injection
|
All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e.
stable VA for three consecutive monthly assessments performed while on ranibizumab treatment).
Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity.
Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of Participants With Systemic Drug-related Adverse Events
大体时间:Baseline to Month 12
|
Monitoring and recording all adverse events, including serious adverse events.
|
Baseline to Month 12
|
Number of Eyes With Ocular Drug-related Adverse Events
大体时间:Baseline to Month 12
|
Monitoring and recording all adverse events, including serious adverse events.
|
Baseline to Month 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Overall Number of Ranibizumab Injections
大体时间:Baseline to month 12
|
Baseline to month 12
|
|
Time Interval Between Injections in Bilateral Disease
大体时间:Baseline to month 12
|
Mean number of days between two consecutive injections per eye
|
Baseline to month 12
|
Mean Number of Injections Per Patient
大体时间:Baseline to month 12
|
Number of injections per patient
|
Baseline to month 12
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CRFB002AIT02
- 2013-003333-15 (EudraCT编号)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
ranibizumab的临床试验
-
Hoffmann-La Roche完全的
-
Hoffmann-La Roche招聘中新生血管性年龄相关性黄斑变性比利时, 美国, 英国, 意大利, 阿根廷, 西班牙, 以色列, 澳大利亚, 奥地利, 巴西, 德国, 瑞士, 台湾, 法国
-
Hoffmann-La Roche招聘中新生血管性年龄相关性黄斑变性 (nAMD)比利时, 大韩民国, 德国, 西班牙, 英国, 澳大利亚, 意大利, 阿根廷, 以色列, 奥地利, 巴西, 法国, 新加坡, 瑞士, 台湾, 火鸡